Ronald J. Loggers
Keine laufenden Positionen mehr
Profil
Mr. Ronald Loggers is Chairman at ISA Pharmaceuticals BV.
He is on the Board of Directors at Schreiner Luchtvaart Groep BV.
Mr. Loggers was previously employed as a Managing Director by Multifund BV.
Mr. Loggers received his graduate degree from the Delft University of Technology and an MBA from INSEAD.
Ehemalige bekannte Positionen von Ronald J. Loggers
| Unternehmen | Position | Ende |
|---|---|---|
Multifund BV
 Multifund BV Investment ManagersFinance Multifund BV is an independent investment adviser headquartered in Reeuwijk, Netherlands and was founded in 2002. Multifund manages diversified assets. | Vorstandsvorsitzender | 01.07.2014 |
| Schreiner Luchtvaart Groep BV | Direktor/Vorstandsmitglied | 28.04.2014 |
ISA Pharmaceuticals BV
 ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Vorstandsvorsitzender | - |
Ausbildung von Ronald J. Loggers
| INSEAD | Masters Business Admin |
| Delft University of Technology | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
ISA Pharmaceuticals BV
ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Health Technology |
Multifund BV
Multifund BV Investment ManagersFinance Multifund BV is an independent investment adviser headquartered in Reeuwijk, Netherlands and was founded in 2002. Multifund manages diversified assets. | Finance |
| Schreiner Luchtvaart Groep BV | Consumer Durables |
